Vertex Pharmaceuticals (VRTX) 10-K Summary — Year Ended Dec 31, 2024
Vertex Pharmaceuticals reported revenue growth but a net loss, largely due to the acquisition of Alpine. The company's liquidity decreased as a result of the cash paid for the acquisition.
Key takeaway
Year ended Dec 31, 2024 · FY2025 10-K
Vertex Pharmaceuticals reported revenue growth but a net loss, largely due to the acquisition of Alpine. The company's liquidity decreased as a result of the cash paid for the acquisition.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$11B
Revenue reported for the fiscal year.
Operating income
-$232.9M
Income from operations reported for the year.
Net income
-$535.6M
Net income reported for the year.
Operating cash flow
-$492.6M
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $7.6B | n/a |
| Dec 31, 2022 | $8.9B | +17.9% |
| Dec 31, 2023 | $9.9B | +10.5% |
| Dec 31, 2024 | $11B | +11.7% |
Business overview
Vertex Pharmaceuticals is a pharmaceutical company. Its business is described in Item 1 of the filing, though the specific details are not included in the supplied data.
Financial performance
Revenue increased compared to the prior year, but the company reported an operating loss and a net loss. Operating cash flow was negative, primarily due to the cash paid to acquire Alpine.
Material risks
The company faces risks related to the integration and financial impact of the Alpine acquisition, which contributed to a net loss and negative operating cash flow. Additionally, the reported operating loss indicates a risk to profitability.
Liquidity and capital
Total cash and marketable securities decreased due to the acquisition, but the company still maintains a substantial balance. Working capital declined significantly, reflecting the cash used for the Alpine acquisition.
What to watch
Monitor the company's progress in integrating Alpine and its path to returning to profitability and positive operating cash flow.